Stephen Gardner to Lamivudine
This is a "connection" page, showing publications Stephen Gardner has written about Lamivudine.
Connection Strength
1.254
-
Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol. 2008 May; 48(5):728-35.
Score: 0.306
-
Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B. J Hepatol. 2005 Feb; 42(2):173-9.
Score: 0.247
-
Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology. 2002 Jul; 36(1):186-94.
Score: 0.207
-
Pharmacokinetic properties of single-dose lamivudine/adefovir dipivoxil fixed-dose combination in healthy Chinese male volunteers. Clin Ther. 2013 Jan; 35(1):68-76.
Score: 0.107
-
Predictors of virologic response to Lamivudine treatment in children with chronic hepatitis B infection. Pediatr Infect Dis J. 2004 May; 23(5):441-5.
Score: 0.059
-
Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology. 2004 Jan; 126(1):81-90.
Score: 0.057
-
Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003 Dec; 125(6):1714-22.
Score: 0.057
-
Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology. 2003 Apr; 37(4):748-55.
Score: 0.054
-
Histological outcome during long-term lamivudine therapy. Gastroenterology. 2003 Jan; 124(1):105-17.
Score: 0.054
-
A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis. Liver Transpl. 2003 Jan; 9(1):49-56.
Score: 0.054
-
Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med. 2002 May 30; 346(22):1706-13.
Score: 0.051